The immediate delisting threat is resolved, but the one-year Mandatory Panel Monitor with no 180-day grace period means the stock must consistently trade above $1.00. Monitor daily closing bid prices closely — any sustained dip below $1.00 for 30 consecutive days would trigger a delist determination. The revenue growth cited (816% YoY) is from a prior press release and reflects a low-base effect from the Future Pak out-license; watch for the Q1 2026 10-Q for absolute revenue and cash runway details.
Price Chart
Executive Summary
Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance with the $1.00 bid price rule, removing immediate delisting risk. However, the Nasdaq Hearings Panel will maintain jurisdiction until September 1, 2026, and the company is subject to a Mandatory Panel Monitor through May 26, 2027, during which any 30-consecutive-business-day bid price failure would trigger a delist determination without the standard 180-day grace period.
Key Facts
- Jaguar regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) as of May 26, 2026.
- Nasdaq Hearings Panel retains jurisdiction over the listing until September 1, 2026.
- Company is subject to a Mandatory Panel Monitor for one year through May 26, 2027.
- During the monitoring period, a failure to maintain a $1.00 closing bid price for 30 consecutive business days will result in a delist determination without the standard 180-day grace period.
- CEO Lisa Conte cited Q1 2026 net revenue increased 816% vs Q1 2025 and 527% vs Q4 2025, driven by the Future Pak out-license agreement for Mytesi and Canalevia-CA1.
- Company is targeting an NDA submission in mid-2027 for its crofelemer powder-for-oral-solution formulation for rare intestinal failure indications.
Financial Impact
No direct financial impact from the compliance notice itself; the company reported Q1 2026 net revenue growth of 816% YoY and 527% QoQ, but no absolute dollar figures were provided in this filing.
Risk Factors
- Mandatory Panel Monitor through May 26, 2027 — any 30-day bid price failure triggers delist process without standard grace period.
- Panel retains jurisdiction until September 1, 2026, allowing potential additional conditions.
- Revenue growth is from a licensing deal with Future Pak; sustainability and cash generation remain unproven.
- Pre-revenue for the lead pipeline candidate (crofelemer) with NDA target in mid-2027 — no near-term product revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-240645 |
| Document: d129501dex991.htm | 0001193125-26-240645 |
| Document: 0001193125-26-240645-index-headers.html | 0001193125-26-240645 |
| Document: 0001193125-26-240645-index.html | 0001193125-26-240645 |
| Document: 0001193125-26-240645.txt | 0001193125-26-240645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers